Lixisenatide: what the studies show

Adlyxin and Soliqua

Lixisenatide alone was approved in the United States as Adlyxin for adults with type 2 diabetes, alongside diet and exercise. FDA lists Adlyxin as discontinued. Its March 2026 label still describes once-daily subcutaneous administration within one hour before the first meal.

Soliqua 100/33 contains both insulin glargine and lixisenatide. It has its own FDA label for adults with type 2 diabetes. Soliqua includes basal insulin, so Adlyxin's instructions do not apply to the combination. Naming lixisenatide alone leaves out that ingredient.

What the trials found

GetGoal-Mono enrolled 361 adults not taking glucose-lowering medicines. At 12 weeks, lixisenatide improved HbA1c and post-meal glucose versus placebo. Weight fell in all groups, so that result does not establish weight-loss superiority.

ELIXA studied people with type 2 diabetes after a recent acute coronary syndrome. It met the trial's cardiovascular safety comparison, called noninferiority, without demonstrating superiority. Whether lixisenatide prevents cardiovascular events better than usual care remains unproven by that trial.

Record whether insulin is included

Record the exact pen name and active ingredients. Soliqua includes insulin, while Adlyxin does not. Their shared lixisenatide component does not make their schedules interchangeable.